(0)サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1689657

抗体受託製造市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)

Antibodies Contract Manufacturing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 250 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
抗体受託製造市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)
出版日: 2025年03月25日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の抗体受託製造市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・促進要因・課題など、重要な市場ダイナミクスを徹底的に評価し、市場構造に関する詳細な洞察を提供しています。この調査レポートは、2025年から2032年までの世界の抗体受託製造市場の予測成長軌道を概説する独占データと統計を掲載しています。

主要な洞察

  • 抗体受託製造の市場規模 (2025年)：66億1,000万米ドル
  • 市場規模の予測 (金額ベース、2032年)：149億5,000万米ドル
  • 世界市場の成長率 (CAGR、2025～2032年)：12.3%

抗体受託製造市場：分析範囲

抗体受託製造は、抗体の製造を専門の開発・製造業務受託機関（CDMO）に委託するものです。これらの組織は、上流および下流の処理、分析特性評価、規制対応、大規模生産に関する専門知識を提供します。この市場は、治療・診断用途のモノクローナル抗体やポリクローナル抗体の開発に従事する製薬会社、バイオテクノロジー企業、研究機関を対象としています。市場成長の原動力は、生物製剤に対する需要の増加、バイオプロセス技術の進歩、効率性と費用対効果を高めるためのアウトソーシング傾向の高まりです。

市場成長の促進要因：

世界の抗体受託製造市場は、がん、自己免疫疾患、感染症の治療におけるモノクローナル抗体の需要の高まりなど、いくつかの重要な要因によって推進されています。個別化医療や標的療法へのシフトが、抗体製造に特化する必要性をさらに高めています。シングルユース・バイオリアクター、連続バイオプロセス、ハイスループットスクリーニング技術の進歩により、製造効率とスケーラビリティが向上しています。さらに、バイオベンチャー企業の増加と自社製造の高コストが、抗体製造をCDMOに委託する傾向を後押ししています。

市場の抑制要因：

有望な成長見通しにもかかわらず、抗体受託製造市場は厳しい規制要件、高い製造コスト、知的財産権に関する懸念などの課題に直面しています。生物製剤の製造は複雑であるため、適正製造基準（GMP）に準拠する必要があり、承認までの期間が長くなり、運用コストが高くなります。さらに、品質管理、汚染リスク、サプライチェーンの混乱に関連する懸念が、契約製造業者に課題を突きつけています。新興市場では、熟練した労働力の利用可能性が限られていることやインフラの制約が、市場の拡大をさらに妨げています。

市場機会：

抗体受託製造市場は、バイオシミラーの採用拡大、CDMO能力の拡大、バイオ生産の技術革新によって大きな成長機会がもたらされます。抗体薬物複合体（ADC）や二重特異性抗体の需要の高まりは、受託製造業者に有利な展望をもたらします。さらに、バイオプロセスにおける人工知能（AI）と自動化の統合は、生産効率を高め、市場投入までの時間を短縮します。バイオ製薬企業とCDMOの戦略的提携、合併、買収は、市場成長の新たな道筋を生み出すと期待されています。アジア太平洋やラテンアメリカなどの新興地域へのCDMOサービスの拡大は、市場浸透をさらに促進します。

当レポートで回答する主な質問

  • 世界の抗体受託製造市場の成長を促す主な要因は何か？
  • 受託製造の需要が最も高い抗体のタイプや製造技術は？
  • 技術の進歩は市場の競合情勢をどのように変えているか？
  • 抗体受託製造市場に貢献している主要企業はどこか？また市場の関連性を維持するためにどのような戦略をとっているのか？
  • 世界の抗体受託製造市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 主な動向
  • マクロ経済要因
    • 世界の部門別の展望
    • 世界のGDP成長の見通し
  • COVID-19の影響分析
  • 予測要因：関連性と影響

第3章 付加価値の洞察

  • 製品採用分析
  • 規制状況
  • バリューチェーン分析
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の抗体受託製造市場の展望

  • 主なハイライト
    • 市場規模と前年比成長率 (10億米ドル)
    • 絶対的収益機会
  • 市場規模の分析と予測 (10億米ドル)
    • 過去の市場規模の分析 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測 (10億米ドル、2025～2032年)
  • 世界の抗体受託製造市場の展望：製品別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：製品別 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測：製品別 (10億米ドル、2025～2032年)
      • モノクローナル抗体
      • 抗体断片
      • 抗体薬物複合体（ADC）
      • その他
    • 市場魅力分析：製品別
  • 世界の抗体受託製造市場の展望：発現系別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：発現系別 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測：発現系別 (10億米ドル、2025～2032年)
      • 哺乳類
      • 微生物
        • 細菌
        • 酵母
    • 市場魅力分析：発現系別
  • 世界の抗体受託製造市場の展望：企業規模別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：企業規模別 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測：企業規模別 (10億米ドル、2025～2032年)
      • 小企業
      • 中企業
      • 大企業
      • 巨大企業
  • 市場魅力分析：企業規模別
  • 世界の抗体受託製造市場の展望：事業段階別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：事業段階別 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測：事業段階別 (10億米ドル、2025～2032年)
      • 前臨床
      • 臨床
      • 実用化
    • 市場魅力分析：事業段階別

第5章 世界の抗体受託製造市場の展望：地域別

  • 主なハイライト
  • 過去の市場規模の分析：地域別 (10億米ドル、2019～2024年)
  • 現在の市場規模の分析と予測：地域別 (10億米ドル、2025～2032年)
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第6章 北米の抗体受託製造市場の展望

第7章 欧州の抗体受託製造市場の展望

第8章 東アジアの抗体受託製造市場の展望

第9章 南アジア・オセアニアの抗体受託製造市場の展望

第10章 ラテンアメリカの抗体受託製造市場の展望

第11章 中東・アフリカの抗体受託製造市場の見通し

第12章 競合情勢

  • 市場シェア分析 (2025年)
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル (詳細：概要、財務、戦略、最近の動向)
    • Lonza
    • Boehringer Ingelheim International GmbH
    • Emergent
    • Eurofins Scientific
    • Thermo Fisher Scientific
    • AbbVie Inc.
    • Catalent Inc.
    • KBI Biopharma
    • Aldevron
    • Novasep
    • Nitto Avecia Pharma Services
    • Pierre Fabre
    • Samsung Biologics
    • Synthon
    • WuXi Biologics
    • Charles River Laboratories
    • FUJIFILM Holdings Corporation
    • mAbxience

第13章 付録

  • 分析手法
  • 分析の前提条件
  • 頭字語と略語
目次
Product Code: PMRREP32933

Persistence Market Research has recently released a comprehensive report on the global antibodies contract manufacturing market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global antibodies contract manufacturing market from 2025 to 2032.

Key Insights:

  • Antibodies Contract Manufacturing Market Size (2025E): USD 6.61 Billion
  • Projected Market Value (2032F): USD 14.95 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 12.3%

Antibodies Contract Manufacturing Market -

Report Scope:

Antibodies contract manufacturing involves the outsourcing of antibody production to specialized contract development and manufacturing organizations (CDMOs). These organizations provide expertise in upstream and downstream processing, analytical characterization, regulatory compliance, and large-scale production. The market caters to pharmaceutical companies, biotechnology firms, and research institutions engaged in the development of monoclonal and polyclonal antibodies for therapeutic and diagnostic applications. Market growth is driven by increasing demand for biologics, advancements in bioprocessing technologies, and the rising trend of outsourcing to enhance efficiency and cost-effectiveness.

Market Growth Drivers:

The global antibodies contract manufacturing market is propelled by several key factors, including the growing demand for monoclonal antibodies in treating cancer, autoimmune diseases, and infectious diseases. The shift towards personalized medicine and targeted therapies has further fueled the need for specialized antibody production capabilities. Advancements in single-use bioreactors, continuous bioprocessing, and high-throughput screening technologies have enhanced manufacturing efficiency and scalability. Additionally, the increasing number of biotech startups, coupled with the high costs of in-house production, has driven the preference for outsourcing antibody manufacturing to CDMOs.

Market Restraints:

Despite promising growth prospects, the antibodies contract manufacturing market faces challenges such as stringent regulatory requirements, high production costs, and intellectual property concerns. The complexity of biologics manufacturing necessitates compliance with Good Manufacturing Practice (GMP) standards, leading to longer approval timelines and higher operational costs. Additionally, concerns related to quality control, contamination risks, and supply chain disruptions pose challenges for contract manufacturers. Limited availability of skilled workforce and infrastructure constraints in emerging markets further hinder market expansion.

Market Opportunities:

The antibodies contract manufacturing market presents significant growth opportunities driven by the increasing adoption of biosimilars, expansion of CDMO capabilities, and technological innovations in bioproduction. The growing demand for antibody-drug conjugates (ADCs) and bispecific antibodies offers lucrative prospects for contract manufacturers. Moreover, the integration of artificial intelligence (AI) and automation in bioprocessing enhances production efficiency and reduces time-to-market. Strategic partnerships, mergers, and acquisitions among biopharma companies and CDMOs are expected to create new avenues for market growth. Expanding CDMO services to emerging regions, such as Asia-Pacific and Latin America, further enhances market penetration.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the antibodies contract manufacturing market globally?
  • Which antibody types and production technologies are witnessing the highest demand in contract manufacturing?
  • How are technological advancements reshaping the competitive landscape of the market?
  • Who are the key players contributing to the antibodies contract manufacturing market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global antibodies contract manufacturing market?

Competitive Intelligence and Business Strategy:

Leading players in the global antibodies contract manufacturing market, including Lonza Group, Samsung Biologics, and WuXi Biologics, focus on expanding production capacities, technological advancements, and strategic collaborations to gain a competitive edge. These companies invest in state-of-the-art biomanufacturing facilities, continuous bioprocessing, and quality control measures to ensure regulatory compliance and high product quality. Collaborations with pharmaceutical firms, biotechnology startups, and research organizations drive market expansion and facilitate innovation in antibody production. Additionally, emphasis on flexible manufacturing solutions, personalized medicine, and biosimilar development contributes to the evolving landscape of contract antibody manufacturing.

Key Companies Profiled:

  • Aldevron
  • Boehringer Ingelheim International GmbH
  • Emergent
  • Eurofins Scientific
  • KBI Biopharma
  • Lonza
  • Novasep
  • Nitto Avecia Pharma Services
  • Pierre Fabre
  • Samsung Biologics
  • Synthon
  • Thermo Fisher Scientific
  • AbbVie Inc.
  • Catalent Inc.
  • WuXi Biologics
  • Charles River Laboratories
  • FUJIFILM Holdings Corporation
  • mAbxience

Key Segments Covered in Antibody Contract Manufacturing Market Segmentation

By Product:

  • Monoclonal Antibodies
  • Antibody Fragments
  • Antibody-Drug Conjugates (ADCs)
  • Others

By Expression System:

  • Mammalian
  • Microbial
  • Bacteria
  • Yeast

By Company Size:

  • Small
  • Mid-sized
  • Large
  • Very large

By Scale of Operation:

  • Preclinical
  • Clinical
  • Commercial

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Oceania
  • East Asia
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Antibodies Contract Manufacturing Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
  • 3.4. PESTLE Analysis
  • 3.5. Porter's Five Force Analysis

4. Global Antibodies Contract Manufacturing Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Antibodies Contract Manufacturing Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Monoclonal Antibodies
      • 4.3.3.2. Antibody Fragments
      • 4.3.3.3. Antibody-Drug Conjugates (ADCs)
      • 4.3.3.4. Others
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Antibodies Contract Manufacturing Market Outlook: Expression System
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn), By Expression System, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Expression System, 2025-2032
      • 4.4.3.1. Mammalian
      • 4.4.3.2. Microbial
        • 4.4.3.2.1. Bacteria
        • 4.4.3.2.2. Yeast
    • 4.4.4. Market Attractiveness Analysis: Expression System
  • 4.5. Global Antibodies Contract Manufacturing Market Outlook: Company Size
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn), By Company Size, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025-2032
      • 4.5.3.1. Small
      • 4.5.3.2. Mid-sized
      • 4.5.3.3. Large
      • 4.5.3.4. Very large
    • 4.5.4. Market Attractiveness Analysis: Company Size
  • 4.6. Global Antibodies Contract Manufacturing Market Outlook: Scale of Operation
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
      • 4.6.3.1. Preclinical
      • 4.6.3.2. Clinical
      • 4.6.3.3. Commercial
    • 4.6.4. Market Attractiveness Analysis: Scale of Operation

5. Global Antibodies Contract Manufacturing Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia & Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Antibodies Contract Manufacturing Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Expression System
    • 6.2.4. By Company Size
    • 6.2.5. By Scale of Operation
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Monoclonal Antibodies
    • 6.4.2. Antibody Fragments
    • 6.4.3. Antibody-Drug Conjugates (ADCs)
    • 6.4.4. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Expression System, 2025-2032
    • 6.5.1. Mammalian
    • 6.5.2. Microbial
      • 6.5.2.1. Bacteria
      • 6.5.2.2. Yeast
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025-2032
    • 6.6.1. Small
    • 6.6.2. Mid-sized
    • 6.6.3. Large
    • 6.6.4. Very large
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 6.7.1. Preclinical
    • 6.7.2. Clinical
    • 6.7.3. Commercial
  • 6.8. Market Attractiveness Analysis

7. Europe Antibodies Contract Manufacturing Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Expression System
    • 7.2.4. By Company Size
    • 7.2.5. By Scale of Operation
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Monoclonal Antibodies
    • 7.4.2. Antibody Fragments
    • 7.4.3. Antibody-Drug Conjugates (ADCs)
    • 7.4.4. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Expression System, 2025-2032
    • 7.5.1. Mammalian
    • 7.5.2. Microbial
      • 7.5.2.1. Bacteria
      • 7.5.2.2. Yeast
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025-2032
    • 7.6.1. Small
    • 7.6.2. Mid-sized
    • 7.6.3. Large
    • 7.6.4. Very large
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 7.7.1. Preclinical
    • 7.7.2. Clinical
    • 7.7.3. Commercial
  • 7.8. Market Attractiveness Analysis

8. East Asia Antibodies Contract Manufacturing Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Expression System
    • 8.2.4. By Company Size
    • 8.2.5. By Scale of Operation
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Monoclonal Antibodies
    • 8.4.2. Antibody Fragments
    • 8.4.3. Antibody-Drug Conjugates (ADCs)
    • 8.4.4. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Expression System, 2025-2032
    • 8.5.1. Mammalian
    • 8.5.2. Microbial
      • 8.5.2.1. Bacteria
      • 8.5.2.2. Yeast
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025-2032
    • 8.6.1. Small
    • 8.6.2. Mid-sized
    • 8.6.3. Large
    • 8.6.4. Very large
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 8.7.1. Preclinical
    • 8.7.2. Clinical
    • 8.7.3. Commercial
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Antibodies Contract Manufacturing Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Expression System
    • 9.2.4. By Company Size
    • 9.2.5. By Scale of Operation
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Monoclonal Antibodies
    • 9.4.2. Antibody Fragments
    • 9.4.3. Antibody-Drug Conjugates (ADCs)
    • 9.4.4. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Expression System, 2025-2032
    • 9.5.1. Mammalian
    • 9.5.2. Microbial
      • 9.5.2.1. Bacteria
      • 9.5.2.2. Yeast
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025-2032
    • 9.6.1. Small
    • 9.6.2. Mid-sized
    • 9.6.3. Large
    • 9.6.4. Very large
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 9.7.1. Preclinical
    • 9.7.2. Clinical
    • 9.7.3. Commercial
  • 9.8. Market Attractiveness Analysis

10. Latin America Antibodies Contract Manufacturing Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Expression System
    • 10.2.4. By Company Size
    • 10.2.5. By Scale of Operation
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Monoclonal Antibodies
    • 10.4.2. Antibody Fragments
    • 10.4.3. Antibody-Drug Conjugates (ADCs)
    • 10.4.4. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Expression System, 2025-2032
    • 10.5.1. Mammalian
    • 10.5.2. Microbial
      • 10.5.2.1. Bacteria
      • 10.5.2.2. Yeast
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025-2032
    • 10.6.1. Small
    • 10.6.2. Mid-sized
    • 10.6.3. Large
    • 10.6.4. Very large
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 10.7.1. Preclinical
    • 10.7.2. Clinical
    • 10.7.3. Commercial
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Antibodies Contract Manufacturing Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Expression System
    • 11.2.4. By Company Size
    • 11.2.5. By Scale of Operation
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Monoclonal Antibodies
    • 11.4.2. Antibody Fragments
    • 11.4.3. Antibody-Drug Conjugates (ADCs)
    • 11.4.4. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Expression System, 2025-2032
    • 11.5.1. Mammalian
    • 11.5.2. Microbial
      • 11.5.2.1. Bacteria
      • 11.5.2.2. Yeast
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Company Size, 2025-2032
    • 11.6.1. Small
    • 11.6.2. Mid-sized
    • 11.6.3. Large
    • 11.6.4. Very large
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2025-2032
    • 11.7.1. Preclinical
    • 11.7.2. Clinical
    • 11.7.3. Commercial
  • 11.8. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Lonza
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Boehringer Ingelheim International GmbH
    • 12.3.3. Emergent
    • 12.3.4. Eurofins Scientific
    • 12.3.5. Thermo Fisher Scientific
    • 12.3.6. AbbVie Inc.
    • 12.3.7. Catalent Inc.
    • 12.3.8. KBI Biopharma
    • 12.3.9. Aldevron
    • 12.3.10. Novasep
    • 12.3.11. Nitto Avecia Pharma Services
    • 12.3.12. Pierre Fabre
    • 12.3.13. Samsung Biologics
    • 12.3.14. Synthon
    • 12.3.15. WuXi Biologics
    • 12.3.16. Charles River Laboratories
    • 12.3.17. FUJIFILM Holdings Corporation
    • 12.3.18. mAbxience

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations